Amylyx Pharmaceuticals


AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Learn More
What is the purpose of this study?

AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the mitochondria and endoplasmic reticulum (ER). This clinical trial is designed to evaluate whether the treatment is safe and able to slow decline due to ALS.

Trial at a Glance


Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gherig’s Disease

Study Intervention

AMX0035 or placebo randomized 2:1

Study Type



Phase 2

Enrollment Goal


Study Identifiers – NCT03127514

Is this Study Right for Me?
18 months
Time Since Symptom Onset


Participation will last for approximately 30-34 weeks, including 24 weeks of treatment, additional screening/baseline assessments taking up to 6 weeks, and 4 weeks of safety follow up after treatment is completed.

Entry Criteria

The staff at your clinical trial site will determine if you meet the criteria for the study. A detailed list of criteria is available at

ALS Diagnosis
Study Locations
This study will recruit at 25 sites across the United States

Site contact information will be update as sites become activated. Please visit again in the near future for up-to-date information regarding the Centaur Trial.